Low-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer with distinct biological behavior. This study aimed to identify new biomarkers with potential diagnostic and prognostic value for LGSOC.

Gene-expression data were downloaded from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were identified using R. Functional enrichment analyses were conducted to determine the biological functions and signaling pathways associated with DEGs. The mitogen-activated protein kinase (MAPK) pathway-related gene, chromosome 1 open reading frame 106 (C1orf106), was selected as the target gene. Immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to verify its expression. Associations between C1orf106 expression and the clinical features of patients were analyzed using the chi-square (χ²) test. Prognostic significance was evaluated with survival analyses.

A total of 3099 upregulated and 4968 downregulated genes were identified in LGSOC. Gene set enrichment analysis (GSEA) demonstrated significant alterations in KRAS signaling and metabolic pathways between LGSOC and healthy controls. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses revealed enrichment in immune response and MAPK pathway alterations. Immunohistochemistry and qRT-PCR confirmed that C1orf106 expression in LGSOC tissues was significantly higher than in normal ovarian tissues. Clinically, high C1orf106 expression was associated with lower BMI (< 25 kg/m²), the absence of visible residual disease, and improved progression-free survival (PFS) and overall survival (OS) in univariate Cox and Kaplan-Meier analyses.

C1orf106 may serve as a promising marker for the diagnosis and prognosis of LGSOC.

The aim of this study was to describe the initial 3-year experience in vein-to-vein time for axi-cel therapy and the role of pharmacists in the first recruiting French centers. Retrospective observational data were collected for vein-to-vein time for commercial axi-cel after ≥ 2 lines of systemic therapy between January 2019 and December 2021 in the first 12 authorized French centers. Hospital pharmacists used a circuit database to ensure the prospective traceability at all steps. Totally 501 of the 562 intention-to-treat registrations on the database for cytapheresis (89,1%) led to the infusion of axi-cel. Median vein-to-vein time was shortened by 4 days. This was mainly due to tightening the interval from apheresis to release. The 36-day median vein-to-vein time achieved after 3 years' experience should be compared to the 29-34 days reported in Canada, the USA and Israel, where manufacturing sites are geographically closer to hospital centers than they are in France. The top 5 recruiting centers had the shortest vein-to-vein times. This French experience may serve as a model for other European centers, notably as regards deployment of pharmacists to improve the patient pathway with CAR T-cells and other gene and cellular therapies.

Radiation Oncology departments impacted by recent cyberattacks were unable to access data backups or their Record and Verify (R&V) system and therefore faced challenges to resume patient treatments in a timely manner. We present a novel software tool that backs-up critical radiotherapy treatment information and displays essential information for on-treatment patients in an intuitive and accessible dashboard allowing clinics to continue radiotherapy treatments. The purpose of this report is to describe implementation details, challenges, and share open-source code to facilitate radiation oncology clinics' efforts to develop tools to improve cyberattack resiliency.

The Radiotherapy Backup and Recovery Dashboard Tool (RBRDT) performs daily backups of treatment information and relationships between DICOM-RT objects from the R&V system and treatment planning system (TPS) to a Radiation Therapy Picture Archiving and Communication System (RT-PACS). If the R&V system is inaccessible, the RBRDT accesses the backed-up data in the RT-PACS to create a dashboard containing critical treatment information for patients currently undergoing radiotherapy.

The RBRDT is successfully clinically implemented and generates backups to the RT-PACS every 10 minutes. Since its implementation in May 2024, the RBRDT backed up over 80,000 RTRECORDS and moved 322 RTPLANS and 142 RTSTRUCTS to the RT-PACS that were absent from this server caused by human error. The dashboard is generated nightly.

The RBRDT fills a critical gap in existing approaches for radiotherapy treatment data backup and restoration. All relational data is transferred to the RT-PACS which is accessible during a cyberattack, reducing the reliance on the R&V system. The RBRDT retrieves connected data elements saved in separate locations. In the event of a cyberattack, this data is returned in a dashboard to rapidly resume patient treatments.

Autoimmune hemolytic anemia-associated diffuse large B cell lymphoma is rare, with distinct pathogenic mechanisms and therapeutic responses in cold agglutinin syndrome (CAS) and warm autoimmune hemolytic anemia subtypes poorly characterized. This report highlights two novel cases demonstrating subtype-specific molecular drivers and treatment outcomes, underscoring the necessity for precision management.

Two patients presented with autoimmune hemolytic anemia: a 29-year-old Han male with cold agglutinin syndrome and a 37-year-old Han female with warm autoimmune hemolytic anemia who had 5-year history of symptoms. Both patients were diagnosed with nongerminal center B cell (nonGCB) diffuse large B cell lymphoma. The male cold agglutinin syndrome-diffuse large B cell lymphoma patient exhibited monoclonal IgM-κ-driven complement-mediated intravascular hemolysis via a direct "tumor-antibody-erythrocyte" axis, accompanied by BCL6 amplification, and achieved rapid remission with rituximab monotherapy. The female warm autoimmune hemolytic anemia-diffuse large B cell lymphoma patient demonstrated polyclonal IgG-mediated macrophage erythrophagocytosis (via the JAK-STAT pathway) and BCL2/BCL6 co-amplification, requiring R-CHOP chemotherapy to control refractory hemolysis.

These cases reveal distinct molecular mechanisms (BCL6 versus BCL2/BCL6 amplification) and therapeutic vulnerabilities in autoimmune hemolytic anemia-diffuse large B cell lymphoma subtypes, requiring subtype-specific treatment. A screening triad-refractory hemolysis, cytopenia, and lymphatic/splenic involvement-enables early lymphoma detection. Molecular profiling may guide precision therapy, improving outcomes in this rare disease spectrum.

Germline pathogenic variants in TP53 cause Li-Fraumeni syndrome, with significantly elevated cancer risk from infancy. Accurate classification of TP53 variants is essential to guide clinical management and surveillance, yet many variants remain classified as variants of uncertain significance (VUS). To improve classification accuracy and reduce the proportion of VUS, the ClinGen TP53 Variant Curation Expert Panel (VCEP) has updated its specifications.

The updated specifications incorporate the latest ClinGen recommendations and methodological advances, providing greater granularity for multiple evidence types, and also introduce the novel use of variant allele fraction as evidence of pathogenicity, particularly in the context of clonal hematopoiesis. Whenever feasible, the VCEP followed a data-driven approach using likelihood ratio-based quantitative analyses to guide code application and determine strength modifications, while also factoring in expert judgment. Proposed modifications were first discussed in working group meetings and then subjected to comprehensive review during monthly general VCEP meetings to reach consensus.

The performance of new specifications was compared to that of the old specifications for 43 pilot variants, and led to both decreased VUS and increased certainty, with clinically meaningful classifications for 93% of variants.

The updated TP53 specfications are expected to reduce VUS rates, increase inter-laboratory concordance, and improve medical management for individuals with germline TP53 variants. The most current version is available at the ClinGen Criteria Specifications Registry (CSpec): https://cspec.genome.network/cspec/ui/svi/svi/GN009 .

Ectopic fat distribution reflects patient's metabolic profile, shaping the tumor microenvironment, which may be a key prognostic indicator. Our study pursues to explore the independent and combined effects of muscle atrophy and abnormal fat distribution on survival in gastric cancer patients.

This retrospective cohort study analyzed body composition in 283 gastric cancer patients from Center Hospital, Tianjin University (June 2016-May 2025) using pretreatment CT at L₃, assessing muscle mass, intermuscular, and visceral fat. Ectopic fat phenotypes included visceral obesity (increased visceral  adipose tissue, VAT) and myosteatosis (reduced skeletal muscle density, SMD). Associations between body composition parameters/phenotypes and progression-free survival (PFS), overall survival (OS), and cachexia-related survival (CRS) were evaluated using Kaplan-Meier analysis with log-rank tests and Cox proportional hazards regression.

Of the 283 patients, 32 patients (11.3%) were BMI-define obese, 139 patients (49.1%) showed visceral obesity, and 176 patients (62.2%) presented with myosteatosis. Sarcopenia was present in 234 patients (82.7%), and 151 patients (53.4%) presented with a combination of sarcopenia and myosteatosis. During a median follow-up of 41 months (2-108 months), 53 patients developed metastasis, 6 relapse, and 142 died. Skeletal muscle mass (Normal Attenuation Muscle Area, NAMA, HR = 0.989, 95% CI 0.980-0.998, P = 0.022, for PFS) and quality (SMD, HR = 0.975, 95% CI 0.955-0.995, P = 0.013, for PFS) serve as protective prognostic factors after multiple covariate adjustments. Multivariate analyses identified all adiposity-related parameters, including Low Attenuation Muscle Area (LAMA, HR = 1.015, 95% CI 1.003-1.026, P = 0.012, for PFS), intermuscular adipose tissue (IMAT, HR = 1.018, 95% CI 1.002-1.034, P = 0.027, for PFS), and VFI (HR = 1.008, 95% CI 1.001-1.015, P = 0.042) as negative indicators for survival. Sensitivity analyses confirmed these associations. Besides, IMAT, LAMA, and VFI significantly influence prognosis in advanced patients (TNM stage III-IV). Kaplan-Meier survival analysis revealed sarcopenic visceral obesity markedly reduces survival; when combined with myosteatosis (SMVO), this combined phenotype further exacerbated CRS (5-year CRS: 74.7% in SMVO, P = 0.019) beyond the effects of individual phenotypes.

Sarcopenic obesity (myosteatosis/visceral obesity) can identify poorer prognosis in gastric cancer patients, especially male patients. It is crucial for obese gastric cancer patients to evaluate their body composition, specifically focusing on fat distribution.

Registered in August 2016, NCT02873676 at www.

gov .

Different degrees of defecation dysfunction have emerged after the sphincter-saving surgery, which has made a significant influence on the quality of life of patients. Although diet adjustments were shown to be important for the management of defecation dysfunction, studies on the dietary management measures for defecation dysfunction after the sphincter-saving surgery are still scarce. This study aims to evaluate the effects of a "remote precise diet management intervention program" on patients with defecation dysfunction after the sphincter-saving surgery, providing a theoretical basis for clinical implementation of feasible diet management, and ultimately improving the quality of life of patients after the sphincter-saving surgery.

This study will be a single-center, prospective, randomized controlled, non-blind trial involving rectal cancer patients after sphincter-saving surgery in a three tertiary general hospital who will be randomized into two groups. The intervention group will apply the "remote precise diet management intervention program" including one-on-one dietary instructions, a written booklet, app-assisted dietary recording and planning, and three times remote consolidating instructions and supervision every 2 weeks. The control group will receive a booklet that contains the same information as that provided in the "remote precise diet management program" and receive the standard counseling that is routinely provided by this hospital about the postoperative diet and Management of bowel symptoms. The intervention will begin from discharge until 6 months after surgery. The primary outcome will be the incidence of LARS after the sphincter-saving surgery. The secondary outcome is the quality of life and the dietary intake of participants after surgery. The occurrence of LARS will be evaluated by the Low Anterior Resection Syndrome Score (LARSS), quality of life, and dietary intake will be separately evaluated by the EORTC-QLQ-C30 questionnaire and Food Frequency Questionnaire(FFQ). Data will be collected three times: the baseline, 3rd month, and 6th month. Statistical analysis will be used to compare the outcomes between groups. Generalized estimating equations (GEEs) will be performed to evaluate the overall effect of the intervention on the incidence of LARS, quality of life, and dietary intake.

The "remote precise diet management intervention program" in this study is designed with the characteristics of scientificity, precision, and feasibility aiming at controlling the bowel symptoms of patients after the sphincter-saving surgery. The findings of the study will provide a theoretical basis for the clinical implementation of feasible diet management, find effective ways to control defecation dysfunction, and ultimately improve the quality of life of patients after the sphincter-saving surgery.

This study has been registered in the Chinese Clinical Trial Registry on March 22nd 2024 (the registration number is ChiCTR2400082167).

The necessity of dissecting station 1 (right paracardial) and 4Sb (left gastroepiploic artery) lymph nodes (LNs) during radical distal gastrectomy for gastric cancer remains debated. This study investigated their therapeutic value for lower-third (LGC) and middle-third (MGC) gastric cancer.

This retrospective cohort study analyzed 897 patients undergoing radical distal gastrectomy (2013-2019). Metastasis rates, clinicopathological associations, multivariate analyses for risk factors and survival and therapeutic value index (TVI = metastasis frequency × 5-year survival of station-positive patients) for stations 1 and 4Sb were assessed, stratified by tumor location.

For LGC (n = 435), station 4Sb showed a 0.46% metastasis rate and a 0% TVI. In contrast, station 1 had a 5.06% metastasis rate and a TVI of 4.14%. Multivariate survival analysis for LGC revealed that after adjusting for T and N stage, station 1 metastasis was not an independent prognostic factor for overall survival (HR 1.60, 95% CI 0.95-2.71, p = 0.078). For MGC (n = 462), station 1 metastasis was an independent prognostic factor (HR 1.75, 95% CI 1.08-2.83, p = 0.023).

Routine dissection of station 4Sb LNs in LGC offers negligible survival benefit. Furthermore, given that station 1 metastasis is not an independent prognostic factor in LGC, its routine dissection also warrants reconsideration. These findings support a biology-driven refinement of lymphadenectomy guidelines, suggesting that omitting station 4Sb and selectively omitting station 1 in LGC may be oncologically safe. Prospective validation is crucial.

Thymic epithelial tumors (TETs) currently lack effective prognostic factors and novel treatment approaches, the aim of the study is to investigate the expression of CD55 in TETs and the relationship with clinicopathological characteristics and prognosis.

Firstly, 250 TETs, including 206 thymoma and 44 thymic squamous cell carcinomas (TSCC), were retrospectively selected. Subsequently, the expression levels of CD55 protein and mRNA were assessed using immunohistochemistry (IHC) and qRT-PCR. Finally, the relationship among CD55, clinicopathological characteristics, and prognosis was analyzed.

The expression of CD55 mRNA and protein were higher in thymoma (p = 0.0148; p < 0.0001) and TSCC (both p < 0.0001) compared with normal thymus tissues. Immunohistochemically, the positive rate of CD55 was 80% (200/250) in TETs, mainly located in cytomembrane. 224 patients were successfully followed up, of which 33 patients developed progression. Univariate Cox regression analysis revealed that histological type, Masaoka-Koga stage, tumor completeness of resection, adjuvant therapy, CD55 mRNA, and protein (all p < 0.01) were significant factors affecting progression free survival (PFS). Multivariate Cox regression analysis showed that CD55 mRNA (p < 0.001), CD55 protein (p = 0.029), tumor completeness of resection (p = 0.010), and Masaoka-Koga stage (p = 0.006) were independent risk factors of PFS. In addition, Pearson's correlation analysis indicated a significant correlation between CD55 mRNA and protein, histological type, tumor completeness of resection, adjuvant therapy, and Masaoka-Koga stage (all p < 0.001). Unpaired T-test showed that the high expression of CD55 mRNA and protein were significantly associated with incomplete resection, higher histological grade, Masaoka-Koga stage, and adjuvant therapy (all p < 0.01). Furthermore, multivariate Cox analysis showed that CD55 mRNA (p < 0.001), CD55 protein (p = 0.037), tumor completeness of resection (p < 0.05) were independent risk factors of PFS in the high-risk TETs subgroup.

The high expression of CD55 was related to poor prognosis of TETs. Moreover, its significant association with worse outcomes in high-risk TETs subgroup further underscores it its potential as a prognostic marker and therapeutic target, especially in TSCC.

Bladder cancer (BC) ranks among the most prevalent ten cancers globally. Current management for BC has seen limited innovation, particularly for advanced stages. Mobile health (mHealth) technologies offer an opportunity to improve BC management by engaging, educating, and empowering patients and assisting physicians, yet available apps are insufficient.

The goal of this study was to provide guidance for designing 'BlaCancer', a mobile app that addresses unfulfilled needs in BC care. We conducted cross-sectional surveys with 16 BC patients and 28 physicians to determine their needs for an mHealth solution.

Patients perceived their levele of understanding of BC as moderate (mean score: 4.75/7), and 68.8% supported mobile apps for education, medical records, and peer support. Physicians stressed the significance of treatment recommendations (89.3%), symptom recording (39.3%), and decision-making tools. Other concerns included data privacy and integration issues.

'BlaCancer' uses stakeholder input to deliver education, symptom monitoring, and clinical decision assistance. The software intends to increase patient participation, improve communication, and streamline aspects of BC care. The small sample size is a limitation that affects generalizability, but the findings still highlight opinions from physicians and patients regarding the role of an app for BC care. Future research will assess the influence on clinical outcomes and quality of life.